ContraVir Pharmaceuticals,Inc. (NASDAQ:CTRV) Files An 8-K Other Events
Item 8.01 Other Events

On January 3, 2017, ContraVir Pharmaceuticals, Inc. (the “Company”) issued a press release announcing that it was awarded a $297,875 CAD research grant from the National Research Council in Canada through the Council’s Industrial Research Assistance Program (IRAP).

The press release is attached as Exhibit 99.1 to this report on Form 8-K and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

99.1 ContraVir Pharmaceuticals, Inc. Press Release dated January 3, 2017

About ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV)

ContraVir Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on the development of antiviral drugs for the treatment of Hepatitis B virus (HBV) infections. The Company develops a range of compounds to treat HBV infection, which include CMX157 and CRV431. The Company is also developing an antiviral asset, FV-100. The Company’s CMX157 is a lipid acyclic nucleoside phosphonate that delivers intracellular concentrations of the active antiviral agent tenofovir diphosphate. The Company has completed a Phase I clinical trial of CMX157. The Company’s CRV431 drug candidate is designed to target cyclophilins, which are a class of proteins. CRV431 inhibits the role of host cyclophilins and interferes in the propagation of the viruses. The Company’s FV-100 is an orally available, small molecule, nucleoside analogue pro-drug of CF-1743, which is used for the treatment of herpes zoster. It has developed FV-100 for the treatment of shingles.

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) Recent Trading Information

ContraVir Pharmaceuticals, Inc. (NASDAQ:CTRV) closed its last trading session up +0.06 at 1.32 with 417,363 shares trading hands.